Your browser doesn't support javascript.
loading
Burden of migraine in Brazil: A cross-sectional real-world study.
Souza, Marcio Nattan Portes; Cohen, Joshua M; Piha, Tony; Ribalov, Rinat; Lengil, Tamar; van der Laan, Andressa; Calderaro, Marcelo; Lee, Lulu K.
Afiliação
  • Souza MNP; Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.
  • Cohen JM; Teva Pharmaceutical Industries, Ltd., West Chester, Pennsylvania, USA.
  • Piha T; Teva Pharmaceutical Industries, São Paulo, Brazil.
  • Ribalov R; Teva Pharmaceutical Industries Ltd., Petah Tikva, Israel.
  • Lengil T; Teva Pharmaceutical Industries Ltd., Petah Tikva, Israel.
  • van der Laan A; Teva Pharmaceutical Industries, São Paulo, Brazil.
  • Calderaro M; Hospital Samaritano Higienópolis, São Paulo, Brazil.
  • Lee LK; Kantar Health, New York, New York, USA.
Headache ; 62(10): 1302-1311, 2022 11.
Article em En | MEDLINE | ID: mdl-36426738
OBJECTIVE: To assess the burden and consequences of migraine in Brazil in terms of health-related quality of life (HRQoL), work productivity and daily activities, and healthcare resource utilization (HRU). BACKGROUND: Despite existing data on how migraine affects populations worldwide, there are limited data on the burden of migraine in Latin America. METHODS: This cross-sectional study used patient-reported data from the 2018 Brazil National Health and Wellness Survey. HRQoL scores (EuroQol 5-dimension 5-level [EQ-5D-5L]; 36-item Short Form Health Survey, version 2 [SF-36v2]; and Short Form 6-dimension [SF-6D]), impairments to work productivity and daily activities (Work Productivity and Activity Impairment questionnaire), and all-cause HRU were compared between migraine respondents and matched non-migraine controls. RESULTS: Of the 12,000 total respondents in the survey database, 1643 self-reported a physician diagnosis of migraine and were propensity score matched 1:1 with controls without migraine. HRQoL was lower in patients with migraine versus non-migraine controls, with significantly lower SF-36v2 physical (mean [± SD] 50.3 [7.5] vs. 52.0 [7.6]) and mental component (mean [± SD] 42.9 [10.2] vs. 46.0 [9.9]) summary scores and SF-6D (mean [± SD] 0.7 [0.1] vs. 0.7 [0.1]) and EQ-5D-5L (mean [± SD] 0.7 [0.2] vs. 0.8 [0.2]) utility scores (all p < 0.001). Patients with migraine reported higher levels of work productivity loss (mean [± SD], 40.6% [31.4%] vs. 28.6% [30.9%], including absenteeism 12.8% [19.1%] vs. 8.4% [17.1%] and presenteeism 35.0% [28.7%] vs. 24.8% [28.0%]; all p < 0.001); activity impairment (mean [± SD] 36.0% [28.8%] vs. 25.5% [28.1%]; p < 0.001); and significantly higher HRU in the past 6 months (healthcare provider and emergency department visits [mean [± SD] 7.2 [9.5] vs. 4.5 [6.3] and 1.7 [3.8] vs. 0.9 [2.2]; both p < 0.001] and hospitalizations [mean [± SD] 0.4 [2.7] vs. 0.2 [1.1]; p = 0.002]) than controls. CONCLUSION: Migraine is associated with poorer HRQoL, higher all-cause HRU, and greater activity impairment and work productivity loss versus non-migraine controls in Brazil.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Transtornos de Enxaqueca Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Headache Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Transtornos de Enxaqueca Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Headache Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos